MedTrace Logo

The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States

NCT06374134 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-04-18

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate an empirical relationship between community- engagement practices, and between patient-centric clinical trial design, execution and communication practices, and vaccine adoption experience.

Our hypothesis is that patient-centric clinical trial activity, and community engagement in late-stage clinical trials and early-stage commercialization, reduces vaccine hesitancy and increases vaccine confidence among health care providers overall and within diverse patient communities and ultimately drives faster vaccine adoption.

Conditions

  • Vaccine Hesitancy

Interventions

BEHAVIORAL

Community Engagement Practice

Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.

BEHAVIORAL

Patient-Centric Protocol Element

Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.

Sponsors & Collaborators

Principal Investigators

  • Kenneth Getz, MBA · Tufts Center for the Study of Drug Development

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-11-30
Completion
2025-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06374134 on ClinicalTrials.gov